Search results for "Mabs" in Articles / App Notes
Article
Cleaning Protein A Resins with 1 M NaOH
Download application note
For more information, visit MabSelect Protein A resins
Article
Reducing Cross-Contamination Risks in Process Chromatography
Preferred target molecules
A variety of biologics benefit from the use of disposable technology in their production, from monoclonal antibodies (mAbs) and recombinant medicines to vaccines and…
Article
Downstream Processing for Cell-Based Therapies
Unlike the traditional manufacture of monoclonal antibodies (mAbs) and other biologics, the production and processing of cellular material forms the basis of the product for CGTs (1). As such, manufac…
Article
Single-use Bioreactors Have Reached the Big Time
The decision to use disposable bioreactors is now driven by commercial rather than technological considerations.
By Cynthia A. Challener
Single-use bioreactors available from various vendors…
Article
Walk Away and Do More Screening Preps
Developing a process or looking for a clone of interest often requires screening large numbers of samples. Many analyses require purified protein, and substantial hands-on time might be allocated to…
Article
Fed-batch supplements to boost cell culture performance
To increase the yield of a target protein, fed-batch culture is often employed in biomanufacturing processes. This application note demonstrates the enhanced performance of commonly used cell lines …
Article
Best Practices in Qualification of Single-Use Systems
The author discusses the current best practices in technical qualification of single-use systems.
By Weibing Ding, PhD
Single-use technology has been around for approximately two decades if …
Article
Use of Multivariate Data Analysis in Bioprocessing
Amanullah, mAbs, 2 (5), pp. 466-479 (September 2010).
2. A. S. Rathore and R. Mhatre, Eds., Quality by Design for Biopharmaceuticals (John Wiley & Sons, Hoboken, NJ, 2009).
3. A.S. Rathore, N.…
Article
Tackling Analytical Method Development for ADCs
Capillary isoelectric focusing (cIEF), such as imaged cIEF, has been a reasonable substitute, but experience with monoclonal antibodies (mAbs) suggests that there may be differences in the information…
Article
High-Throughput Process Development in an Historical Environment
Genentech is said to be working with less than 20 different formulations, developed mainly for mAbs, but these formulations have also been shown to work for other types of target molecules. Instead, t…